Cargando…
Pharmacokinetics and Bioavailability of a Therapeutic Enzyme (Idursulfase) in Cynomolgus Monkeys after Intrathecal and Intravenous Administration
Intravenous enzyme replacement therapy with iduronate-2-sulfatase is an approved treatment for Hunter syndrome, however, conventional intravenous delivery cannot treat the neurologic manifestations of the disease due to its limited central nervous system penetration. Intrathecal administration of id...
Autores principales: | Xie, Hongsheng, Chung, Jou-Ku, Mascelli, Mary Ann, McCauley, Thomas G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383552/ https://www.ncbi.nlm.nih.gov/pubmed/25836678 http://dx.doi.org/10.1371/journal.pone.0122453 |
Ejemplares similares
-
Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration
por: Chung, Jou-Ku, et al.
Publicado: (2016) -
Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA
por: Chung, Jou-Ku, et al.
Publicado: (2017) -
CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
por: Calias, Pericles, et al.
Publicado: (2012) -
Intrathecal catheter implantation decreases cerebrospinal fluid dynamics in cynomolgus monkeys
por: Khani, Mohammadreza, et al.
Publicado: (2020) -
Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
por: Mao, Cheng-Ping, et al.
Publicado: (2013)